HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

Merck & Co., Inc. MRK gained FDA approval for its supplemental new drug applications (sNDAs) looking for label expansion of its two new HIV drugs — Pifeltro and Delstrigo.

Merck MRK recently launched two late-stage clinical studies to evaluate MK-8527, its investigational once-monthly oral pill for HIV pre-exposure prophylaxis (PrEP). The EXPrESSIVE-11 study, which ...

The new drug application is supported by 48-week data from the Phase III MK-8591A-051 and MK-8591A-052 trials, which showed ...

After marquee HIV drug approvals last year for Gilead and GlaxoSmithKline, Merck will follow into the crowded market with two new meds. The drugmaker scored FDA approvals for a new non-nucleoside ...

SAN FRANCISCO (MarketWatch) -- Merck & Co. said late Friday it received accelerated approval from the Food and Drug Administration for Isentress tablets, a drug to treat HIV-1 infection.

Merck MRK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval for its ...

Merck on Thursday said the application covers the investigational, once-daily, oral two-drug regimen for adults with HIV-1 infection that is virologically suppressed on antiretroviral therapy. The ...

President Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S., but not immediately ...

Aug 30 (Reuters) - Drugmaker Merck & Co Inc said on Thursday the U.S. Food And Drug Administration approved two of its oral medicines to treat HIV patients. U.S. regulators approved Delstrigo, a ...

It went where other drug companies feared to tread and got a big-selling HIV drug. ... Hazuda's baby, Isentress, was approved in 2006 and was Merck's fastest growing medicine last quarter.

If regulators make routine cell monitoring of islatravir patients a condition of approval, they could kill off the chances of the drug becoming a significant commercial product for Merck. While ...